Lumentum jumps after bright Q2 revenue forecast, Q1 results beat
ReutersNov 5, 2025 10:25 AM
Shares of optical and photonic products maker Lumentum LITE.O jump 16.3% to $219.1 premarket
LITE forecasts Q2 revenue in the range of $630 mln-$670 mln, above analysts' average estimate of $560.2 mln, according to data compiled by LSEG
Reports Q1 revenue of $533.8 mln, beating estimates of $525.4 mln; adj. EPS of $1.1 also tops estimates
At least two brokerages raise PT on stock post results
16 of 20 brokerages covering the stock rate it "buy" or higher and four "hold"; the median PT is $180
As of last close, LITE shares have more than doubled in 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
What Drove the 'Black Tuesday' Sell-Off? Three Key Factors Behind the U.S. Stock Plunge
TradingKey - On November 4, 2025, U.S. markets suffered a sudden and sharp selloff — dubbed “Black Tuesday” — with the Nasdaq posting its largest single-day drop in a month. The rout unfolded amid growing economic and political instability, as a record-long government shutdown worsened systemicTradingKey
3 hours ago
IonQ Stock Price Skyrockets 300% in a Year, But Recently Drops 30%—Is IonQ Still a Buy?
Is IonQ worth buying? With a recent decline of nearly 30% over the past month, is now the time to buy? How much further could IonQ's stock rise?TradingKey
5 hours ago
The Tariff Refund Drama Begins: Five Major Impacts If Trump Loses the Supreme Court Case
TradingKey - A landmark legal battle with clear undertones of “small business vs. government” will unfold at the U.S. Supreme Court on November 5, a case President Donald Trump has called “the most important in American history.” The ruling will directly determine the legality of Trump’s signatureTradingKey
23 hours ago
Novo Nordisk Q3 Earnings Preview: New CEO, Board Overhaul — Can the U.S. Weight-Loss Market Turn Around?
TradingKey - Novo Nordisk (NVO), one of Europe’s pharmaceutical giants and a leader in the weight-loss drug race, will report its Q3 2025 earnings before market open on November 5. Wall Street expects a modest rebound from Q2’s worst growth in four years, but significant pressure on profits remains.TradingKey
Tue, Nov 4
Palantir Q3 2025 Earnings: Blowout Performance Can’t Hide an AI Bubble， Four Growing Risks Behind a Nearly 1,000x Valuation
TradingKey – After the close of trading on November 4, “AI application King” Palantir Technologies (PLTR) reported its third-quarter earnings for fiscal year 2025. Despite a blowout quarter, surging top-line growth, and a flood of commercial orders, the stock plunged in after-hours trading.TradingKey
Tue, Nov 4
